0

Rho-kinase Inhibitor Y-27632 Attenuates Pulmonary Hypertension in Hyperoxia-Exposed Newborn Rats

Hsiu-Chu Chou, Liang-Ti Huang, Tsu-Fu Yeh, Chung-Ming Chen

Acta Pharmacol Sin. 2013 Oct;34(10):1310-6.

PMID: 23974518

Abstract:

Aim:
To test the hypothesis that neonatal hyperoxia induced pulmonary hypertension accompanied by increased Rho-kinase expression in rat lungs and that Rho-kinase inhibitor could attenuate right ventricular hypertrophy and pulmonary arterial remodeling.
Methods:
Newborn rats were exposed to >95% O2 in the first week after birth, then to 60% O2 in the following 2 weeks. Control pups were exposed to room air over the same periods. The pups were injected with either Rho-kinase inhibitor Y-27632 (10 mg·kg(-1)·d(-1), ip) or vehicle from postnatal d 14 to 20. Lung and heart tissues were collected on postnatal d 7 and 21. Rho-kinase activity in lungs was measured using Western blotting and immunohistochemistry. The right ventricular hypertrophy and arterial medial wall thickness (MWT) were assessed morphologically.
Results:
Rho-kinase activity in lungs was comparable between the hyperoxic and control pups on postnatal d 7, but it had a more than 2-fold increase in the hyperoxic pups on postnatal d 21. Moreover, the hyperoxic exposure induced structural features of pulmonary hypertension, as shown by the right ventricular hypertrophy and significantly increased arterial MWT. Administration with Y-27632 effectively blocked the hyperoxia-induced increase of Rho-kinase activity in lungs, and attenuated the right ventricular hypertrophy.
Conclusion:
Rho-kinase inhibitor may be a novel therapy for attenuating the hyperoxia-induced structural changes in pulmonary hypertension.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
IAR42415733 Rho Kinase Inhibitor Rho Kinase Inhibitor Price
qrcode